Miller Investment Management LP decreased its position in Becton Dickinson and Co (NYSE:BDX) by 7.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,777 shares of the medical instruments supplier’s stock after selling 725 shares during the quarter. Becton Dickinson and comprises approximately 0.5% of Miller Investment Management LP’s holdings, making the stock its 22nd largest position. Miller Investment Management LP’s holdings in Becton Dickinson and were worth $2,212,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. FMR LLC raised its position in shares of Becton Dickinson and by 5.0% during the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after purchasing an additional 842,590 shares during the period. Ronna Sue Cohen raised its position in shares of Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after purchasing an additional 5,710,365 shares during the period. JPMorgan Chase & Co. raised its position in shares of Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after purchasing an additional 416,459 shares during the period. Fundsmith LLP raised its position in shares of Becton Dickinson and by 0.9% during the first quarter. Fundsmith LLP now owns 3,771,159 shares of the medical instruments supplier’s stock worth $941,772,000 after purchasing an additional 35,453 shares during the period. Finally, Northern Trust Corp raised its position in shares of Becton Dickinson and by 0.7% during the first quarter. Northern Trust Corp now owns 3,223,811 shares of the medical instruments supplier’s stock worth $805,082,000 after purchasing an additional 23,645 shares during the period. Institutional investors and hedge funds own 85.07% of the company’s stock.
BDX stock traded down $1.41 during mid-day trading on Wednesday, hitting $247.74. The stock had a trading volume of 216,118 shares, compared to its average volume of 1,214,724. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. Becton Dickinson and Co has a 1-year low of $208.62 and a 1-year high of $265.87. The business’s fifty day moving average price is $252.03. The stock has a market cap of $68.66 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 1.85 and a beta of 1.11.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share for the quarter, topping the consensus estimate of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The company had revenue of $4.35 billion for the quarter, compared to analyst estimates of $4.37 billion. During the same period in the prior year, the firm posted $2.91 EPS. The business’s revenue was up 1.7% compared to the same quarter last year. As a group, equities analysts anticipate that Becton Dickinson and Co will post 11.68 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 1.24%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is currently 27.97%.
In other Becton Dickinson and news, Director Claire Fraser sold 1,429 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $243.26, for a total value of $347,618.54. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Samrat S. Khichi sold 16,085 shares of the company’s stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total value of $3,774,827.80. Following the completion of the transaction, the executive vice president now directly owns 12,608 shares in the company, valued at $2,958,845.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,529 shares of company stock worth $5,836,116. Insiders own 0.12% of the company’s stock.
Several research analysts recently weighed in on the company. Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. BMO Capital Markets dropped their price target on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research report on Friday, May 10th. Barclays raised Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target on the stock in a research report on Monday, May 13th. UBS Group dropped their price target on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, May 10th. Finally, ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $264.27.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: Bond
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.